ALRN

Aileron Therapeutics, Inc.

2.22 USD

Last updated Dec 10, 08:22 UTC

Yesterday HIGH

$2.43

Yesterday LOW

$2.11

52w HIGH

$3.3

52w LOW

$1.01

EPS

-0.4

PE

-5.55

Next Earnings

Mar 18, 2024

Overview News Insider Transactions Government Trades

Aileron Therapeutics, Inc. stock is up 24.72% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. Company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

Bill Haddad

Tue Feb 21, 2023

Aileron Therapeutics Announces Termination Of Phase 1b Breast Cancer Chemoprotection Trial And Exploration Of Strategic Alternatives

Aileron Therapeutics (NASDAQ:ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial
Happy Mohamed

Tue Feb 21, 2023

Aileron Therapeutics Shares Halted, News Pending
Benzinga Insights

Wed Dec 28, 2022

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 258 companies hit new 52-week lows.
Benzinga Insights

Wed Dec 21, 2022

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 152 stocks made new 52-week lows.
Benzinga Newsdesk

Thu Nov 10, 2022

Aileron Therapeutics Announces A 1-For-20 Reverse Stock Split
Benzinga Newsdesk

Tue Nov 1, 2022

Aileron Therapeutics Q3 EPS $(0.07), Same YoY

Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(0.07) per share. This is unchanged from the same period last year.
Benzinga Newsdesk

Wed Oct 26, 2022

Aileron Therapeutics Presents Results From Phase 1 Study In Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest On Bone Marrow Stem Cells And Hair Follicles At EORTC-NCI-AACR International Conference

p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss) Study showed
Benzinga Newsdesk

Fri Sep 30, 2022

Aileron Therapeutics Announces Oral Presentation Of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles And Their Stem Cells From Chemotherapy-Induced Damage At The European Society For Dermatological Research Annual Meeting 2022

New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells Encore presentation of data presented at Society for Investigative Dermatology in May
Benzinga Insights

Tue Sep 20, 2022

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Lisa Levin

Thu Sep 15, 2022

Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday

Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.

Ladenburg Thalmann

Fri Dec 1, 11:40

buy

upgrade

Advanced Data Unlock

WINDSOR JAMES BRIAN, President and COO

Mon Nov 20, 2023

ALRN Recent Insider Trades and Stock Chart

5,076 shares bought

Advanced Data Unlock

ALB $128.04 USD

CHEF $28.05 USD

EXEL $21.99 USD

SSD $181.94 USD

COLL $27.33 USD

AKRO $19.91 USD